Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Cynthia Ann Lemere, Ph.D.

Co-Author

This page shows the publications co-authored by Cynthia Lemere and Dennis Selkoe.
Connection Strength

1.542
  1. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci. 2000; 920:328-31.
    View in: PubMed
    Score: 0.222
  2. The AMY antigen co-occurs with abeta and follows its deposition in the amyloid plaques of Alzheimer's disease and down syndrome. Am J Pathol. 1999 Jul; 155(1):29-37.
    View in: PubMed
    Score: 0.215
  3. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. 1996 Feb; 3(1):16-32.
    View in: PubMed
    Score: 0.169
  4. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. Am J Pathol. 1995 Apr; 146(4):848-60.
    View in: PubMed
    Score: 0.160
  5. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug; 14(8):837-42.
    View in: PubMed
    Score: 0.100
  6. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004 Jul; 165(1):283-97.
    View in: PubMed
    Score: 0.076
  7. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003 Oct; 14(1):10-8.
    View in: PubMed
    Score: 0.072
  8. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002 Jun; 9(2):88-102.
    View in: PubMed
    Score: 0.066
  9. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 2001 Nov; 20(11):705-11.
    View in: PubMed
    Score: 0.063
  10. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol. 2000 Oct; 48(4):567-79.
    View in: PubMed
    Score: 0.059
  11. Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol. 2000 Feb; 156(2):489-99.
    View in: PubMed
    Score: 0.056
  12. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med. 1996 Oct; 2(10):1146-50.
    View in: PubMed
    Score: 0.044
  13. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016 May 06; 352(6286):712-716.
    View in: PubMed
    Score: 0.043
  14. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med. 1995 Dec; 1(12):1291-6.
    View in: PubMed
    Score: 0.042
  15. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol. 1992 Jul; 141(1):249-59.
    View in: PubMed
    Score: 0.033
  16. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis. 2009 Nov; 36(2):293-302.
    View in: PubMed
    Score: 0.027
  17. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008 Apr 16; 28(16):4231-7.
    View in: PubMed
    Score: 0.025
  18. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005 May; 11(5):556-61.
    View in: PubMed
    Score: 0.020
  19. A seed for Alzheimer amyloid in the brain. J Neurosci. 2004 May 19; 24(20):4894-902.
    View in: PubMed
    Score: 0.019
  20. The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem. 1996 Dec 27; 271(52):33623-31.
    View in: PubMed
    Score: 0.011
  21. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis. 1996 Feb; 3(1):51-63.
    View in: PubMed
    Score: 0.011
  22. Lysosomal processing of amyloid precursor protein to A beta peptides: a distinct role for cathepsin S. Biochem J. 1995 Oct 01; 311 ( Pt 1):299-305.
    View in: PubMed
    Score: 0.010
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.